Rhythm Biosciences (ASX:RHY) completed the first sale of the blood-based ColoSTAT colorectal cancer test, according to a Wednesday filing with the Australian bourse.
The company will scale up test volumes directly with physicians and through its ColoSTAT Access Program, the filing said.
Shares rose nearly 13% in morning trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.